HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Quinuclidines

A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.

Also Known As:

Quinuclidine

Networked: 20 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Bridged-Ring Heterocyclic Compounds
  - Quinuclidines: 20

Experts

1.	Arisawa, Hirohiko: 4 articles (01/2002 - 01/2002)
2.	Fukui, Kenji: 4 articles (01/2002 - 01/2002)
3.	Masunaga, Hiroaki: 4 articles (01/2002 - 01/2002)
4.	Fujise, Nobuaki: 3 articles (01/2002 - 01/2002)
5.	Imai, Eiichi: 2 articles (01/2002 - 01/2002)
6.	Dos Santos, Tiago: 1 article (04/2022)
7.	Fernandes, Ana R: 1 article (04/2022)
8.	Garcia, Maria L: 1 article (04/2022)
9.	Granja, Pedro L: 1 article (04/2022)
10.	Sanchez-Lopez, Elena: 1 article (04/2022)

Related Diseases

1.	Xerostomia 01/01/2002 - "A novel muscarinic receptor agonist, SNI-2011 ((+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] monohydrochloride hemihydrate, cevimeline, CAS 153504-70-2), is a candidate therapeutic drug for xerostomia in Sjögren's syndrome. " 01/01/2002 - "A novel muscarinic receptor agonist SNI-2011 ((+/-)-cis-2-methylspirol[1,3-oxathiolane-5,3'-quinuclidine] monohydrochloride hemihydrate, cevimeline, CAS 153504-70-2), is a candidate therapeutic drug for xerostomia in Sjögren's syndrome. " 01/01/2002 - "A novel muscarinic receptor agonist, SNI-2011 ((+/-)-cis-2-methylspiro[1,3-oxathiolane- 5,3'-quinuclidine]monohydrochloride hemihydrate, cevimeline, CAS 153504-70-2), is a candidate therapeutic drug for xerostomia in Sjögren's syndrome. " 01/01/2002 - "A novel muscarinic receptor agonist, SNI-2011 ((+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] monohydrochloride hemihydrate, cevimeline, CAS 153504-70-2), is a candidate therapeutic drug for xerostomia in Sjögren's syndrome. " 11/01/1998 - "We investigated effects of (+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride), a rigid analogue of acetylcholine, on saliva and tear secretions in rats and mice to evaluate its therapeutical efficacy for xerostomia and xerophthalmia in patients with Sjogren's syndrome and X-ray exposure in the head and neck. "
2.	Xerophthalmia 11/01/1998 - "We investigated effects of (+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride), a rigid analogue of acetylcholine, on saliva and tear secretions in rats and mice to evaluate its therapeutical efficacy for xerostomia and xerophthalmia in patients with Sjogren's syndrome and X-ray exposure in the head and neck. "
3.	Sjogren's Syndrome (Sjogren Syndrome) 11/01/1998 - "We investigated effects of (+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride), a rigid analogue of acetylcholine, on saliva and tear secretions in rats and mice to evaluate its therapeutical efficacy for xerostomia and xerophthalmia in patients with Sjogren's syndrome and X-ray exposure in the head and neck. "
4.	Cognitive Dysfunction 07/31/1989 - "(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats." 04/01/1991 - "(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease."
5.	Chronic Obstructive Pulmonary Disease (COPD) 04/15/2008 - "Alkyne-quinuclidine derivatives as potent and selective muscarinic antagonists for the treatment of COPD." 09/01/2017 - "Two-step strategy was implemented for Umeclidinium bromide (UMEC) analysis which is a novel quinuclidine-based muscarinic antagonist used for maintenance treatment of symptoms accompanied with chronic obstructive pulmonary disease. "

Related Drugs and Biologics

1.	cevimeline (Evoxac)
2.	Acetylcholine (Acetylcholine Chloride)
3.	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
4.	Pilocarpine (Ocusert)
5.	imidazole
6.	Muscarinic Antagonists
7.	Muscarinic M1 Receptor
8.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
9.	Nicotinic Antagonists
10.	Muscarinic Agonists